Lung resection for metastatic osteogenic sarcoma

Publisher Website
Google Scholar
Abstract
Osteogenic sarcoma, excluding the paraosteal osteosarcoma, has a grave prognosis, half of the patients dying within 1 year following ablative surgery of the primary lesion. Once pulmonary metastasis is detected, most patients do not survive more than 3 years. Various attempts by investigators to prolong patient survival, including surgery, chemotherapy, immunotherapy, radiation therapy, and combined modalities, have met with some success. This report is a summary of 13 patients who underwent lung resections and received adjuvant chemo- and/or immunotherapy for metastatic osteogenic sarcoma in our institute in the past 7 years.

This publication has 2 references indexed in Scilit: